Trial Profile
Sodium glucose cotransporter inhibitor 2, Tofogliflozin versus glimepiride, comparative trial in Patients with type 2 diabetes On Body composition (STOP-OB study)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2021
Price :
$35
*
At a glance
- Drugs Tofogliflozin (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms STOP-OB study
- 27 Feb 2019 Status changed from recruiting to completed.
- 01 Oct 2018 Results published in the Diabetes Therapy
- 08 May 2017 Status changed from not yet recruiting to recruiting.